Girentuximab-Zr-89Alternative Names: 89Zr-girentuximab; Zirconium-89 girentuximab; Zr-89-girentuximab
Latest Information Update: 14 Sep 2016
At a glance
- Originator WILEX AG
- Developer Radbound University Nijmegen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Natural killer cell stimulants; Positron-emission tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Renal cell carcinoma